Great Wall Guorui Securities released a research report on April 18 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) steady growth in performance and improvement in overall profitability; 2) continuing to increase investment in research and development in the pharmaceutical industry, and several innovative drugs are expected to be launched within the year; 3) medical and aesthetic maintenance of rapid growth and the introduction of two differentiated botulinum toxin products. (Mainichi Keizai Shimbun)
长城国瑞证券4月18日发布研报称，给予华东医药（000963.SZ）买入评级。评级理由主要包括：1）业绩稳健增长，整体盈利能力提升；2）持续加大医药工业研发投入，多个创新药有望年内上市；3）医美保持快速增长，引进两款差异化肉毒素产品。（每日经济新闻）
Great Wall Guorui Securities released a research report on April 18 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) steady growth in performance and improvement in overall profitabil
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.